Table 3 The clinical trials of IDH inhibitors
NCT number | Conditions | Interventions | Phase | Number enrolled |
|---|---|---|---|---|
NCT04176393 | R/R AML | Ivosidenib | Phase 1 | 30 |
NCT03564821 | IDH1-mutated myeloid neoplasms | Ivosidenib | Phase 1 | 18 |
NCT03245424 | AML | Ivosidenib | NA | NA |
NCT02074839 | R/R AML/MDS/other IDH1-mutated positive hematologic malignancies | Ivosidenib | Phase 1 | 291 |
NCT03839771 | AML/MDS | Ivosidenib | Phase 3 | 968 |
NCT03503409 | AML/MDS | Ivosidenib | Phase 2 | 68 |
NCT05282459 | AML | Enasidenib | Phase 1/2 | 48 |
NCT04203316 | R/R AML | Enasidenib | Phase 2 | 10 |
NCT03515512 | AML/CML | Enasidenib | Phase 1 | 23 |
NCT01915498 | Hematologic neoplasms | Enasidenib | Phase 1 | 345 |
NCT03720366 | AML | Enasidenib | Phase 1 | 40 |
NCT03728335 | AML | Enasidenib | Phase 1 | 15 |
NCT03881735 | R/R AML | Enasidenib | Phase 2 | 0 |
NCT03744390 | AML/MDS | Enasidenib | Phase 2 | 68 |
NCT03723057 | AML | Enasidenib | NA | NA |
NCT04522895 | AML/MDS/CML | Enasidenib | Phase 2 | 50 |
